Home/News Feed/BridgeBio's Attruby revenue soars 134% YoY; FDA decision for BBP-418 due Nov 27 BridgeBio reported a 134% year-over-year increase in net product revenue for Attruby, reaching $253.2 million in Q3 2026, driven by new patients starting treatment for transthyretin amyloid cardiomyopathy. The company anticipates an FDA decision on November 27, 2026, for BBP-418, a potential treatment for limb-girdle muscular dystrophy type 2I, with confidence in full approval. Additionally, priority reviews for infigratinib and encaleret could lead to new rare disease therapy launches in 2027. BridgeBio holds $1.5 billion in cash and securities, supporting upcoming launches and clinical development while aiming for operational breakeven.
BridgeBio Pharma Inc (BBIO) shares are trading at USD 76.03 on Pluang as of Nov 23, 2026 04:31 WIB, down 2.75% for the day. The stock's market cap stands at $14.81 billion, reflecting significant investor interest amid upcoming FDA decisions. Typical hold time for BBIO on Pluang is 65 days, indicating moderate trading activity among retail investors.